Css LLC Il Buys Shares of 9,940 Incyte Co. (NASDAQ:INCY)

CSS LLC IL purchased a new position in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,940 shares of the biopharmaceutical company's stock, valued at approximately $687,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INCY. Quintet Private Bank Europe S.A. bought a new stake in Incyte during the fourth quarter worth about $26,000. Global X Japan Co. Ltd. increased its position in shares of Incyte by 144.7% during the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 230 shares during the last quarter. R Squared Ltd bought a new stake in shares of Incyte during the 4th quarter worth approximately $30,000. Raiffeisen Bank International AG acquired a new stake in shares of Incyte in the 4th quarter valued at approximately $34,000. Finally, Blue Trust Inc. boosted its holdings in shares of Incyte by 124.6% in the 4th quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 329 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Incyte Stock Performance

Shares of NASDAQ INCY traded up $1.24 during trading hours on Tuesday, reaching $65.49. 224,422 shares of the stock were exchanged, compared to its average volume of 2,304,534. The firm has a market capitalization of $12.68 billion, a price-to-earnings ratio of 242.65, a P/E/G ratio of 0.41 and a beta of 0.68. The stock's fifty day simple moving average is $60.52 and its 200 day simple moving average is $67.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. Incyte Co. has a 52 week low of $53.56 and a 52 week high of $83.95.

Incyte (NASDAQ:INCY - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.15. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $996.17 million. During the same period in the prior year, the firm posted $0.64 EPS. The company's revenue for the quarter was up 19.5% on a year-over-year basis. Sell-side analysts predict that Incyte Co. will post 4.86 EPS for the current year.

Insider Activity at Incyte

In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of the firm's stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the transaction, the executive vice president now owns 25,848 shares in the company, valued at $1,914,561.36. This trade represents a 35.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction on Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the transaction, the executive vice president now directly owns 33,567 shares of the company's stock, valued at $2,272,150.23. This represents a 37.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,475 shares of company stock worth $2,424,751. Corporate insiders own 17.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on INCY shares. Royal Bank of Canada boosted their target price on shares of Incyte from $64.00 to $67.00 and gave the stock a "sector perform" rating in a report on Wednesday, April 30th. William Blair lowered shares of Incyte from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 18th. Citigroup cut their target price on shares of Incyte from $97.00 to $88.00 and set a "buy" rating for the company in a research note on Tuesday, February 11th. JPMorgan Chase & Co. reduced their price target on Incyte from $70.00 to $68.00 and set a "neutral" rating for the company in a report on Monday, April 21st. Finally, JMP Securities restated a "market perform" rating on shares of Incyte in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $73.60.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.